Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Guardant Health gets equity and loan commitments totaling $100mm in Series D round

Executive Summary

Guardant Health Inc. (liquid biopsies for cancer) completed the first closing of a $100mm Series D round, which includes equity and a term loan facility. OrbiMed led and was joined by existing backers Khosla Ventures, Sequoia Capital, Lightspeed Venture Partners, Pejman Mar, Formation 8, Heritage Group, and others. The money will support commercialization of Guardant360, a noninvasive 70-gene genome sequencing test (liquid biopsy) for cancer.
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement
    • Nonconvertible Debt

Related Companies

Advertisement
UsernamePublicRestriction

Register